Opiant Pharmaceuticals, Inc.

NasdaqCM:OPNT Stok Raporu

Piyasa değeri: US$108.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Opiant Pharmaceuticals CEO'su Roger Crystal, Sep2009 tarihinde atandı, in görev süresi 13.5 yıldır. in toplam yıllık tazminatı $ 1.48M olup, şirket hissesi ve opsiyonları dahil olmak üzere 42.9% maaş ve 57.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.64% ine doğrudan sahiptir ve bu hisseler $ 695.26K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 6.8 yıldır.

Anahtar bilgiler

Roger Crystal

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi42.9%
CEO görev süresi13.5yrs
CEO sahipliği0.6%
Yönetim ortalama görev süresi5.5yrs
Yönetim Kurulu ortalama görev süresi6.8yrs

Son yönetim güncellemeleri

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21
Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19
Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09
Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06
The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05
News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27
Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

CEO Tazminat Analizi

Roger Crystal'un ücretlendirmesi Opiant Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$1mUS$635k

US$3m

Sep 30 2021n/an/a

US$2m

Jun 30 2021n/an/a

-US$1m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$1mUS$610k

-US$2m

Sep 30 2020n/an/a

-US$108k

Jun 30 2020n/an/a

US$10m

Mar 31 2020n/an/a

US$12m

Dec 31 2019US$1mUS$592k

US$12m

Sep 30 2019n/an/a

US$988k

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$865kUS$574k

-US$21m

Sep 30 2018n/an/a

-US$2m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017n/an/a

US$3m

Oct 31 2017n/an/a

US$2m

Jul 31 2017US$1mUS$568k

US$7m

Apr 30 2017n/an/a

US$6m

Jan 31 2017n/an/a

US$9m

Oct 31 2016n/an/a

US$3m

Jul 31 2016US$5mUS$616k

-US$8m

Tazminat ve Piyasa: Roger 'nin toplam tazminatı ($USD 1.48M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 650.00K ).

Tazminat ve Kazançlar: Roger şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Roger Crystal (46 yo)

13.5yrs

Görev süresi

US$1,477,846

Tazminat

Dr. Roger Crystal, M.D., has been an Independent Director of Mind Medicine (MindMed) Inc. since August 11, 2022. Dr. Crystal has been the Chief Executive Officer of Opiant Pharmaceuticals, Inc. since Septe...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Roger Crystal
President13.5yrsUS$1.48m0.64%
$ 695.3k
David O'Toole
Chief Financial Officer5.5yrsUS$786.67k0.43%
$ 464.9k
Phillip Skolnick
Chief Scientific Officer6.1yrsUS$800.11k0.19%
$ 202.6k
Ben Atkins
Vice President of Communications & Investor Relationsno dataVeri yokVeri yok
Brian Gorman
EVP Corporate Development & General Counsel2.6yrsVeri yok0.34%
$ 369.9k
Mark Ellison
Chief Development Officerno dataVeri yok0.36%
$ 387.2k
Matthew Ruth
Chief Commercial Officer1.7yrsVeri yok0.13%
$ 137.7k

5.5yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: OPNT 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Roger Crystal
President13.5yrsUS$1.48m0.64%
$ 695.3k
Michael Sinclair
Independent Director12.3yrsUS$42.70k1.14%
$ 1.2m
Thomas Thomas
Independent Director6.3yrsUS$113.70k0.20%
$ 214.2k
Craig Collard
Independent Chairman4.4yrsUS$137.20k1.02%
$ 1.1m
Thomas Kosten
Member of Medical Advisory Boardno dataVeri yokVeri yok
Ann MacDougall
Independent Director6.8yrsUS$109.70k0.50%
$ 540.6k
Sharon Walsh
Chairwoman of Medical Advisory Boardno dataVeri yokVeri yok
Sandra Comer
Member of Medical Advisory Boardno dataVeri yokVeri yok
Marc Potenza
Member of Medical Advisory Boardno dataVeri yokVeri yok
Gabrielle Silver
Independent Director6.8yrsUS$103.70k0.41%
$ 440.7k
Stephanie O'Malley
Member of Medical Advisory Boardno dataVeri yokVeri yok
Wim van den Brink
Member of Medical Advisory Boardno dataVeri yokVeri yok

6.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OPNT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).